Published in Cancer Weekly, November 24th, 1997
The kit received 510(k) clearance for a monitoring claim, adding to the 1996 U.S. marketing clearance of Truquant BR blood test kit as an aid in the detection of recurrent breast cancer.
Biomira launched its Truquant BR RIA blood test kit for the detection of recurrent breast cancer in the U.S. in 1996, after a three-year clinical trial in patients previously treated for Stage II or Stage III...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.